Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1066 to 1080 of 1257 results for pathway

  1. Partial replacement of the meniscus of the knee using a biodegradable scaffold (HTG289)

    Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.

    HealthTech guidance
    Published
    23 July 2012
    View recommendations

    Sections for HTG289

  2. Past research and projects

    NICE's past research and projects

  3. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

    Medtech innovation briefing
    Published
    21 May 2020

  4. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

    Medtech innovation briefing
    Published
    18 January 2017

  5. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

    Medtech innovation briefing
    Published
    14 September 2016

  6. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

    Medtech innovation briefing
    Published
    23 March 2016

  7. Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social anxiety disorder?

    uptake and engagement, including: - Development and evaluation of improved pathways into care, in collaboration with low users of...

    Research recommendation
    Published
    9 June 2015

  8. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    and may not be conclusive. Understanding and mapping changes in molecular pathways could predict outcome and inform individual treatment...

    Research recommendation
    Published
    4 August 2022

  9. Routine outcome measurement:- In people with a common mental health disorder, what is the clinical utility of routine outcome measurement and is it cost effective compared with standard care?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  10. Generalized Anxiety Disorder scale (GAD-2) for people with suspected anxiety disorders:- In people with suspected anxiety disorders, what is the clinical utility of using the GAD-2 compared with routine case identification to accurately identify different anxiety disorders? Should an avoidance question be added to improve case identification?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  11. Identifying health conditions:- What is the effectiveness and cost effectiveness of different ways of identifying age-related and other physical and mental health conditions, in people growing older with learning disabilities?What can mainstream and specialist health services do to facilitate:- early identification of health conditions in people with learning disabilities?- equal access to health services in people with learning disabilities?

    health checks, we did not find any evidence about different methods and pathways for identifying health conditions among people growing...

    Research recommendation
    Published
    29 November 2018

  12. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

    NICE guideline
    Published
    29 June 2022
    View recommendations

    Sections for NG222

  13. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.

    NICE guideline
    Last updated
    4 February 2025

    Sections for NG209

  14. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA902

  15. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

    Technology appraisal guidance
    Published
    25 May 2022
    View recommendations

    Sections for TA791